natgillin/translations-raw huggingface dataset:
Holoclar består af en gennemsigtigt, rund skive med 300.000 til 1.200.000 levedygtige, autologe, humane corneaepitelceller (79.000-316.000 celler/cm2), herunder gennemsnitligt 3,5 % (0,4-10 %) limbale stamceller, og stamcelleafledte forbigående forstærkende og terminalt differentierede celler, fæstnet til et understøttende fibrinlag på 2,2 cm i diameter og opbevaret i transportmediet.
Holoclar consists of a transparent circular sheet of 300,000 to 1,200,000 viable autologous human corneal epithelial cells (79,000 - 316,000 cells/cm2), including on average 3.5% (0.4 to 10%) limbal stem cells, and stem cell-derived transient amplifying and terminally differentiated cells, attached on a supportive 2.2 cm diameter fibrin layer and maintained in the transport medium.
Holoclar er et lag celler til implantation i dit øje.
Holoclar is a layer of cells for implantation into your eye.
Holoclar er et lægemiddel til avanceret terapi, som kaldes et »produkt fremstillet ved vævsteknik«.
Holoclar is a type of advanced therapy product called a ‘tissue engineered product’.
Holoclar har fået en »betinget godkendelse«.
Holoclar has therefore been given ‘conditional approval’.
Holoclar – som består af cellerne og membranen – sendes derefter retur til hospitalet, hvor det straks implanteres i patientens øje ved operation.
Holoclar, comprising the cells and the membrane, is then sent back to the hospital, where it is immediately surgically implanted in the patient’s eye.
Holoclars virkningsmekanisme er udskiftningen af corneaepitel og mistedelimbale stamceller hos patienter, i hvilke limbus er blevet ødelagt pga. okulære forbrændinger.
The mechanism of action of Holoclar is the replacement of corneal epithelium and lost limbal stem cells in patients in which the limbus has been destroyed by ocular burns.
Hols dosisknappen trykket helt i bund.
Keep the injection button pressed all the way in.
Homogen, mælkehvid injektionsvæske, suspension.
Homogeneous milky white suspension for injection.
Homozygot familiær hyperkolesterolæmi hos voksne og unge i alderen 12 år og opefter
Homozygous familial hypercholesterolaemia in adults and adolescents aged 12 years and over
Honningaroma Renset vand
Honey aroma Purified water
Honningduft
Honey Flavour.
Honningduft Renset vand
Honey aroma Purified water
Honningduft Renset vand
Honey flavour Purified water.
horis
ut
Horizon, Honey Lane Hurley, SL6 6RJ
Horizon, Honey Lane Hurley, SL66RJ
HORIZONS-studiet (patienter med STEMI, der får foretaget primær PCI)
The HORIZONS Trial (Patients with STEMI undergoing primary PCI)
HORIZONS-studiet var et prospektivt, enkeltblindt, randomiseret, multicenterforsøg med to arme udført med henblik på at klarlægge bivalirudins sikkerhed og virkning hos patienter med STEMI, der får foretaget en primær PCI-med stentimplantation med enten en langsomt afgivende paclitaxel- afgivende stent (TAXUS™) eller en i øvrigt identisk stent i bart metal uden overfladebehandling (Express2™).
The HORIZONS trial was a prospective, dual arm, single blind, randomised, multi-centre trial to establish the safety and efficacy of bivalirudin in patients with STEMI undergoing a primary PCI strategy with stent implantation with either a slow release paclitaxel-eluding stent (TAXUS™) or an otherwise identical uncoated bare metal stent (Express2™).
hormon (LH) og
and follicle-stimulating
Hormon depot-injektion,
Hormonal depot injection,
Hormonal
Hormonal receptor
Hormonal prævention, såsom p-piller, injiceret prævention (for eksempel Depo-Provera) eller præventivt implantat (for eksempel Implanon): De skal også anvende pålidelig barriereprævention (se Graviditet og amning).
Hormonal contraceptive, such as birth control pills, an injected contraceptive (for example, Depo-Provera), or a contraceptive implant (for example, Implanon): You must also use a reliable barrier method of contraception (see Pregnancy and breast-feeding).
Hormonale kontraceptiva (se pkt.
Hormonal contraceptives (see section 4.6)
Hormonale kontraceptiva kan fortsat tages, men er muligvis ikke pålidelige under INCIVO-behandling og i op til 2 måneder efter afslutning på denne behandling (se pkt.
Hormonal contraceptives may be continued but may not be reliable during INCIVO dosing and for up to two months following cessation of INCIVO (see section 4.5).
HORMONALE KONTRACEPTIVA/ØSTROGEN
HORMONAL CONTRACEPTIVES/OESTROGEN
Hormonel
Hormonal receptor
Hormonel
unchanged drug;
HORMONEL ANTIKONCEPTION
(increased solubility)
HORMONEL ANTIKONCEPTION
HORMONAL CONTRACEPTIVES
HORMONEL KONTRACEPTION
HORMONAL CONTRACEPTIVES
hormonel kontraception er ikke
contraception during co
Hormonel prævention, såsom p-piller, prævention som indsprøjtning (fx Depo-Provera) eller et kontraceptivt implantat (fx Implanon NXT): De skal også bruge pålidelig barriereprævention (se Graviditet og amning), da Stocrin kan bevirke, at virkningen af hormonel prævention nedsættes.
Hormonal contraceptive, such as birth control pills, an injected contraceptive (for example, Depo-Provera), or a contraceptive implant (for example, Implanon): you must also use a reliable barrier method of contraception (see Pregnancy, breast-feeding and fertility).
Hormonel receptorstatus
0.52-1.01
Hormonel receptorstatus
Hormonal receptor
Hormonelle antikonceptiva må ikke være den eneste præventionsmetode under behandlingen med STAYVEER
Hormonal contraceptives cannot be the sole method of contraception during treatment with STAYVEER
Hormonelle antikonceptiva må ikke være den eneste præventionsmetode under behandlingen med Tracleer
Hormonal contraceptives cannot be the sole method of contraception during treatment with Tracleer
hormonelle graviditetsforebyggende midler,
hormonal contraceptive agents (birth control medicines),
HORMONELLE KONTRACEPTIVA
HORMONAL CONTRACEPTIVES
Hormonelle præventionsmidler (f.eks. p-piller, p-plastre, implantater og visse spiraltyper) virker muligvis mindre effektivt ved samtidig brug af Sivextro.
Contraceptives that release hormones (e.g., birth control pills, skin patches, implants, and certain intrauterine devices [IUDs]) may not work effectively when taken together with this medicine.
Hormonelle præventionsmidler, som indeholder ethinylestradiol, da Norvir kan mindske disse lægemidlers virkning.
Hormonal contraceptives containing ethinyl oestradiol as Norvir may reduce the effectiveness of these medicines.
Hormonelle præventionsmidler: Samtidig administration af bosentan 125 mg to gange dagligt i 7 dage og en enkeltdosis af et oralt kontraceptionsmiddel, der indeholdt norethisteron 1 mg + ethinylestradiol 35 µg reducerede AUC for norethisteron og ethinylestradiol med henholdsvis 14% og 31%.
Hormonal contraceptives: co-administration of bosentan 125 mg twice daily for 7 days with a single dose of oral contraceptive containing norethisterone 1 mg + ethinyl estradiol 35 mcg decreased the AUC of norethisterone and ethinyl estradiol by 14% and 31%, respectively.
Hormonelle præventionsmidler: Samtidig administration af bosentan 125 mg to gange dagligt i 7 dage og en enkeltdosis af et oralt kontraceptionsmiddel, der indeholdt norethisteron 1 mg + ethinylestradiol 35 g, reducerede AUC for norethisteron og ethinylestradiol med henholdsvis 14% og 31%.
Hormonal contraceptives: co-administration of bosentan 125 mg twice daily for 7 days with a single dose of oral contraceptive containing norethisterone 1 mg + ethinyl estradiol 35 mcg decreased the AUC of norethisterone and ethinyl estradiol by 14% and 31%, respectively.
Hormonelle uregelmæssigheder, som kan påvirke salt- og vandoptagelsen
Hormone abnormality which may affect salt and water absorption
hormoner mod overgangsalderen – lægemidler indeholdende østrogen
hormonal replacement therapy - oestrogen-based medicines
Hormonet melatonin spiller en vigtig rolle i reguleringen af kroppens søvnrytme.
A hormone called melatonin plays a key role in co-ordinating the body’s sleep-wake cycle.
Hormonholdige lægemidler til forebyggelse af graviditet som fx p-piller, plastre, implantater og visse former for hormonspiral virker måske ikke tilstrækkeligt, når de tages sammen med EMEND.
birth control medicines which can include birth control pills, skin patches, implants, and certain Intrauterine devices (IUDs) that release hormones may not work adequately when taken together with EMEND.
Hormonholdigt lægemiddel til forebyggelse af graviditet som fx p-piller, plastre, implantater og visse former for hormonspiral virker måske ikke tilstrækkeligt, når de tages sammen med EMEND.
birth control medicines which can include birth control pills, skin patches, implants, and certain Intrauterine devices (IUDs) that release hormones may not work adequately when taken together with EMEND.
HORMONKONTRACEPTIVA
HORMONAL CONTRACEPTIVES
hormonsubstitution/hormonterapi
hormone replacement therapy
Hormonsystemet: Diabetisk ketoacidose (en komplikation, der skyldes ukontrolleret diabetes) Psykiske forstyrrelser og nervesystemet: Selvmord og psykotiske forstyrrelser (svære problemer med personligheden og forringelse af normal social funktion), koma (en dyb vedvarende bevidstløshedstilstand), krampeanfald og ansigtslammelse (svækkelse af ansigtsmusklerne)
Hormone system disorders: Diabetic ketoacidosis, a complication of uncontrolled diabetes Psychiatric and nervous system disorders: Suicide, psychotic disorders (severe problems with personality and deterioration in normal social functioning), coma (a deep prolonged unconsciousness), seizures, facial palsy (weakness of the facial muscle)
Hormonsystemet: Diabetisk ketoacidose (en komplikation, der skyldes ukontrolleret diabetes) Psykiske forstyrrelser og nervesystemet: Selvmord og psykotiske forstyrrelser(svære problemer med personligheden og forringelse af normal social funktion), koma (en dyb vedvarende bevidstløshedstilstand), krampeanfald og ansigtslammelse (svækkelse af ansigtsmusklerne)
Hormone system disorders: Diabetic ketoacidosis, a complication of uncontrolled diabetes Psychiatric and nervous system disorders: Suicide, psychotic disorders (severe problems with personality and deterioration in normal social functioning), coma (a deep prolonged unconsciousness), seizures, facial palsy (weakness of the facial muscle)
Hormonsystemet: For stærk og for svag funktion af skjoldbruskkirtlen
Hormone system disorders: Overactive and underactive thyroid gland
Hornhinde-
(Post-Marketing
Hornhinde-
irritation
Hornhindeerosion, reversibel og til tider i forbindelse med abnorm øjenvippevækst.
Corneal erosion, reversible and sometimes in association with aberrant eyelash growth.
Hornhindeforkalkning i forbindelse med brug af øjendråber, som indeholder phosphat er i meget sjældne tilfælde rapporteret hos patienter med signifikant beskadigede hornhinder.
Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.
Hornhindeforkalkning i forbindelse med brug af øjendråber, som indeholder phosphat, er i meget sjældne tilfælde rapporteret hos patienter med signifikant beskadigede hornhinder.
Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.
Horses: i.v.
Horses: IV
Horses: i.v.
IV injection.
Hos
products.
Hos "ALK-positive" eller "ROS1-positive" patienter er ALK- eller ROS1-proteinet unormalt aktivt og kan fremme vækst af kræftceller og udvikling af nye blodårer, der forsyner disse kræftceller.
In patients either ‘ALK-positive’ or ‘ROS1-positive’, the ALK or ROS1 protein is abnormally active and can promote the growth of cancer cells and the development of new blood vessels that supply them.
Hos 1 % af patienterne, der fik dabrafenib som monoterapi i den integrerede sikkerhedspopulation i de kliniske studier, blev der identificeret alvorlige tilfælde af ikke-infektiøs feber som feber ledsaget af svære kulderystelser, dehydrering, hypotension og/eller akut nyreinsufficiens af prærenal oprindelse hos patienter med normal nyrefunktion ved baseline.
In 1% of patients receiving dabrafenib as monotherapy in the integrated safety population in clinical trials, serious non-infectious febrile events were identified as fever accompanied by severe rigors, dehydration, hypotension and/or acute renal insufficiency or pre-renal origin in subjects with normal baseline renal function.
Hos 1,1 % af patienterne i optrapningsfasen med Viramune 200 mg opstod der svært eller livstruende udslæt, der blev betragtet som nevirapin- relateret.
Severe or life- threatening rash considered related to nevirapine treatment occurred in 1.1 % of patients during the lead-in phase with Viramune immediate-release.
Hos 1. linje-patienter behandlet med enten MabCampath eller chlorambucil var der 21 patienter med 17 q deletion, 54 patienter med 11 q deletion, 34 patienter med trisomi 12, 51 patienter med normal karyotype og 67 patienter med kun 13 q deletion.
In first line patients, treated with either MabCampath or chlorambucil, there were 21 patients with the 17p deletion, 54 patients with 11q deletion, 34 patients with trisomy 12, 51 patients with normal karyotype and 67 patients with sole 13q deletion.
Hos 1.094 patienter med CML i fremskreden fase eller Ph+ ALL var den mediane behandlingsvarighed 6,2 måneder (0-9,32 måneder).
In 1,094 patients with advanced phase CML or Ph+ ALL, the median duration of treatment for patients was 6.2 months (range 0-9.32 months).
Hos 1.715 hypertensive patienter med type 2-diabetes, proteinuri ≥ 900 mg/dag og serum- kreatininværdier i intervallet 1,0-3,0 mg/dl, evalueredes langtidseffekterne (median 2,6 år) ved Aprovel med henblik på progression af nyresygdom og totalmortalitet.
1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Aprovel on the progression of renal disease and all-cause mortality were examined.
Hos 1.715 hypertensive patienter med type 2-diabetes, proteinuri ≥ 900 mg/dag og serum- kreatininværdier i intervallet 1,0-3,0 mg/dl, evalueredes langtidseffekterne (median 2,6 år) ved Irbesartan BMS med henblik på progression af nyresygdom og totalmortalitet.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Irbesartan BMS on the progression of renal disease and all-cause mortality were examined.
Hos 1.715 hypertensive patienter med type 2-diabetes, proteinuri ≥ 900 mg/dag og serum- kreatininværdier i intervallet 1,0-3,0 mg/dl, evalueredes langtidseffekterne (median 2,6 år) ved irbesartan med henblik på progression af nyresygdom og totalmortalitet.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of irbesartan on the progression of renal disease and all-cause mortality were examined.
Hos 1.715 hypertensive patienter med type 2-diabetes, proteinuri ≥ 900 mg/dag og serum- kreatininværdier i intervallet 1,0-3,0 mg/dl, evalueredes langtidseffekterne (median 2,6 år) ved Irbesartan Zentiva med henblik på progression af nyresygdom og totalmortalitet.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Irbesartan Zentiva on the progression of renal disease and all-cause mortality were examined.
Hos 1.715 hypertensive patienter med type 2-diabetes, proteinuri ≥ 900 mg/dag og serum- kreatininværdier i intervallet 1,0-3,0 mg/dl, evalueredes langtidseffekterne (median 2,6 år) ved Karvea med henblik på progression af nyresygdom og totalmortalitet.
1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of renal disease and all-cause mortality were examined.
Hos 10 (2,6 %) og 2 (0,5%) patienter i henholdsvis ”nevirapin 2 gange daglig”- og efavirenzgrupperne blev klinisk hepatitis rapporteret som en klinisk bivirkning.
Clinical hepatitis reported as clinical adverse event occurred in 10 (2.6 %) and 2 (0.5 %) patients in the nevirapine twice daily and efavirenz groups respectively.
Hos 100 af 929 patienter (10,8 %) med massive tumorer blev infusionsrelaterede reaktioner beskrevet under behandling med Caelyx, karakteriseret ved følgende Costart termer: allergisk reaktion, anafylaktoid reaktion, astma, ansigtsødem, hypotension, vasodilatation, urticaria, rygsmerter, brystsmerter, kulderystelser, feber, hypertension, takycardi, dyspepsi, kvalme, svimmelhed, dyspnø, pharyngitis, udslæt, kløe, svedtendens, reaktion på injektionsstedet og lægemiddelinteraktion.
100 out of 929 patients (10.8%) with solid tumours were described as having an infusion-associated reaction during treatment with Caelyx as defined by the following Costart terms: allergic reaction, anaphylactoid reaction, asthma, face oedema, hypotension, vasodilatation, urticaria, back pain, chest pain, chills, fever, hypertension, tachycardia, dyspepsia, nausea, dizziness, dyspnoea, pharyngitis, rash, pruritus, sweating, injection site reaction and medicinal product interaction.
Hos 11 % (5/46) af de børn, der blev behandlet i 24 uger og 13 % (6/48) af de børn, der blev behandlet i 48 uger, var der en reduktion fra baseline før behandling til afslutningen af den 5-årige langtidsopfølgning på > 30 percentiler for alderen.
Eleven percent of children (5/46) treated for 24 weeks and 13 % of children (6/48) treated for 48 weeks were observed to have a decrease from pre treatment baseline > 30 height for age percentiles to the end of the 5 year long term follow-up.
Hos 119 imiquimod behandlende kvinder, var frekvensen 60 % sammenlignet med 20 % hos 105 placebo behandlede kvinder. (95 % CI for forskellen: 20% til 61% p<0,001).
In 119 imiquimod-treated female patients, the combined total clearance rate was 60% as compared to 20% in 105 vehicle-treated patients (95% CI for rate difference: 20% to 61%, p<0.001).
Hos 12 cancerpatienter, der fik en enkelt oral dosis palonosetron 0,5 mg en time før kemoterapi, var Cmaks 0,93 ± 0,34 ng/ml, og Tmaks var
In 12 cancer patients given a single oral dose of palonosetron 0.5 mg one hour prior to chemotherapy, Cmax was 0.93 ± 0.34 ng/mL and Tmax was 5.1 ±
Hos 12 hunde, der led af atopisk dermatitis, blev der ikke observeret nogen særlig effekt på det systemiske kortisolniveau efter topikal applikation på huden med den anbefalede dosering i 28 til 70 på hinanden følgende dage,.
In 12 dogs suffering from atopic dermatitis, after topical application on the skin at the recommended therapeutic dosage for 28 to 70 consecutive days, no noticeable effect on the systemic cortisol level was observed.
Hos 12 patienter med tilgængelige data svarede AUC og Cmax ca. til dem, der blev observeret for 20 mg/kg dosisgruppen i pivotalundersøgelsen.
In 12 patients with available data the AUC and Cmax were approximately equivalent to those observed for the 20 mg/kg dose group in the pivotal trial.
Hos 13 behandlingsnaïve personer på et stabilt regimen med dolutegravir plus abacavir/lamivudin lå koncentrationen af dolutegravir i CSF i gennemsnit på 18 ng/ml (sammenligneligt med plasmakoncentrationen af ubundet dolutegravir, og over IC50-værdien).
In 13 treatment-naïve subjects on a stable dolutegravir plus abacavir/lamivudine regimen, dolutegravir concentration in CSF averaged 18 ng/mL (comparable to unbound plasma concentration, and above the IC50).
Hos 16-26 årige kvinder (protokol 001) er persistent antistofrespons blevet påvist i mindst 3,5 år; afhængigt af HPV-type var 78-98% af forsøgspersonerne seropositive.
In 16-26 year-old women (Protocol 001), persistence of antibody response has been demonstrated for at least 3.5 years; depending on HPV type, 78-98% of subjects were seropositive.
Hos 17 patienter (4,5%), der fik sunitinib, forekom blødning i grad 3 eller højere sammenlignet med 5 (1,7%) patienter, der fik IFN-α.
Seventeen (4.5%) patients on sunitinib versus 5 (1.7%) of patients on IFN-α experienced Grade 3 or greater bleeding events.
Hos 1715 hypertensive patienter med type 2 diabetes, proteinuri ≥ 900 mg/dag og serum- kreatininværdier i intervallet 1,0-3,0 mg/dl, blev langtidseffekterne (median 2,6 år) ved irbesartan med henblik på progression af nyresygdom og total mortalitet evalueret.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of irbesartan on the progression of renal disease and all-cause mortality were examined.
Hos 1715 hypertensive patienter med type 2 diabetes, proteinuri ≥ 900 mg/dag og serum- kreatininværdier i intervallet 1,0-3,0 mg/dl, evalueredes langtidseffekterne (median 2,6 år) ved Irbesartan BMS med henblik på progression af nyresygdom og total mortalitet.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Irbesartan BMS on the progression of renal disease and all-cause mortality were examined.
Hos 1715 hypertensive patienter med type 2-diabetes, proteinuri ≥ 900 mg/dag og serum- kreatininværdier i intervallet 1,0-3,0 mg/dl, evalueredes langtidseffekterne (median 2,6 år) ved Aprovel med henblik på progression af nyresygdom og total mortalitet.
1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Aprovel on the progression of renal disease and all-cause mortality were examined.
Hos 1715 hypertensive patienter med type 2-diabetes, proteinuri ≥ 900 mg/dag og serum- kreatininværdier i intervallet 1,0-3,0 mg/dl, evalueredes langtidseffekterne (median 2,6 år) ved Irbesartan Zentiva med henblik på progression af nyresygdom og total mortalitet.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Irbesartan Zentiva on the progression of renal disease and all-cause mortality were examined.
Hos 1715 hypertensive patienter med type 2-diabetes, proteinuri ≥ 900 mg/dag og serum- kreatininværdier i intervallet 1,0-3,0 mg/dl, evalueredes langtidseffekterne (median 2,6 år) ved Karvea med henblik på progression af nyresygdom og total mortalitet.
1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of renal disease and all-cause mortality were examined.
Hos 2 ud af 14 patienter, som havde akut HIV-infektion ved optagelse i studiet, blev K65R-mutationen påvist i HIV 1 hos 5 forsøgspersoner i tenofovirdisoproxil 245 mg (som fumarat) -gruppen, og M184V-mutationen (forbundet med resistens over for emtricitabin) blev påvist i HIV hos 1 ud af 3 forsøgspersoner i Truvada-gruppen.
In 2 of 14 subjects who had acute HIV infection at study enrollment, the K65R mutation was detected in the HIV of 1 of 5 subjects in the tenofovir disoproxil 245 mg (as fumarate) group and the M184V mutation (associated with resistance to emtricitabine) was detected in the HIV of 1 of 3 subjects in the Truvada group.
Hos 2 ud af 30 hunde i den kliniske undersøgelse, blev infertilitet først opnået 12 uger efter første behandling, men i de fleste tilfælde vil sådanne hunde ikke være i stand til at avle afkom.
In 2 out of 30 dogs in the clinical trial infertility was not achieved until approximately 12 weeks after initial treatment, but in most cases these animals are not capable of successfully siring offspring.
Hos 2.461 patienter behandlet med telithromycin i fase III kliniske studier samt igennem post- marketing erfaring blev følgende bivirkninger, der muligvis eller sandsynligvis kunne relateres til telithromycin, rapporteret.
In 2,461 patients treated by Ketek in phase III clinical trials, and during post-marketing experience, the following undesirable effects possibly or probably related to telithromycin have been reported.